unrelated

Clinical investigators are currently exploring ustekinumab, an IL-12 and IL-23 antagonist, for graft vs host disease (GVHD) prophylaxis in matched unrelated donor hematopoietic cell transplantation (HCT) recipients. A phase 2 …

Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338–48. Article  PubMed  PubMed Central  Google …

Patient characteristics Baseline characteristics of the study population are shown in Table 1. A total of 8,764 patients were included, of whom 7,725 (88%) received his rATG and 1,039 (12%) …